Cyclophillin A deficiency accelerates RML-induced prion disease

Ihssane Bouybayoune, Liliana Comerio, Laura Pasetto, Ilaria Bertani, Valentina Bonetto, Roberto Chiesa

Research output: Contribution to journalArticlepeer-review


Prion diseases typically involve brain deposition of abnormally folded prion protein, which is associated with activated glia and increased cytokine production. Cyclophilin A (CypA) is a ubiquitous protein with peptidyl prolyl cis-trans isomerase activity, which regulates protein folding, and can be secreted by cells in response to inflammatory stimuli. On the basis of in vitro studies, CypA was proposed to mediate glial activation during prion infection. To investigate the role of CypA in vivo, we inoculated CypA+/+, CypA+/- and CypA-/- mice with the RML prion strain, and recorded the time to onset of neurological signs and to terminal disease, and the astrocyte and microglia response at presymptomatic and symptomatic stages. Time to onset of disease and survival were significantly shorter in CypA-deficient mice than CypA-expressing controls. CypA-deficient mice had significantly greater microglial activation in the presymptomatic stage, and analysis of anti- and pro-inflammatory microglial markers indicated a shift towards a pro-inflammatory phenotype. There was no difference in astrocyte activation. This suggests that CypA contributes to dampening the pro-inflammatory microglial response during the early stage of RML-induced prion disease.

Original languageEnglish
Pages (from-to)104498
JournalNeurobiology of Disease
Publication statusPublished - Oct 2019


Dive into the research topics of 'Cyclophillin A deficiency accelerates RML-induced prion disease'. Together they form a unique fingerprint.

Cite this